# Brivanib Metastatic Renal Cell Carcinoma

> **NCT01253668** · PHASE2 · TERMINATED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 10 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Brivanib alaninate
- **GENETIC:** Polymerase chain reaction
- **OTHER:** Iodine I 124 chimeric monoclonal antibody G250
- **PROCEDURE:** Positron emission tomography/computed tomography
- **GENETIC:** Protein expression analysis
- **OTHER:** Immunohistochemistry

## Key facts

- **NCT ID:** NCT01253668
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-11
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** In November 2012, this study was permanently closed to new accrual at the request of the drug manufacturer (BMS), who decided not to pursue additional research activity in this patient population.
- **Last updated:** 2021-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01253668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01253668, "Brivanib Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01253668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*